Sendil Selin, Gjergjindreaj Medeona, Lozier Matthew, Fernandez Rafle
Cardiology, Mount Sinai Medical Center, Miami, USA.
Cureus. 2022 Dec 2;14(12):e32138. doi: 10.7759/cureus.32138. eCollection 2022 Dec.
Obesity is a well-established cardiovascular (CV) risk factor with greater mortality and morbidity rates than the general population. Phentermine is a weight loss medication that is approved for short-term obesity treatment in conjunction with lifestyle modifications to decrease CV risk. A 51-year-old female with Raynaud's phenomenon who was started on phentermine one week prior presented with a one-day history of palpitations. Subsequent workup revealed non-ST elevation myocardial infarction (NSTEMI) on presentation and worsening ST segment depressions following regadenoson injection during pharmacological stress testing. Although current evidence suggests that the use of phentermine is safe and may even reduce the risk of CV disease in obese patients, it still may pose adverse CV effects. A detailed medical history, including medications used and predisposing conditions, is crucial to help identify and possibly prevent exacerbation of such CV side effects.
肥胖是一种公认的心血管（CV）危险因素，其死亡率和发病率高于普通人群。苯丁胺是一种减肥药物，被批准用于短期肥胖治疗，并结合生活方式的改变以降低心血管风险。一名51岁患有雷诺现象的女性，在一周前开始服用苯丁胺，出现心悸一天的病史。随后的检查显示，就诊时为非ST段抬高型心肌梗死（NSTEMI），在药物负荷试验中注射瑞加诺生后ST段压低加重。尽管目前的证据表明，使用苯丁胺是安全的，甚至可能降低肥胖患者患心血管疾病的风险，但它仍可能产生不良心血管效应。详细的病史，包括所使用的药物和易感因素，对于帮助识别并可能预防此类心血管副作用的加重至关重要。
